In contrast, IDH1/2-wild-type gliomas predominantly originated in the temporal lobe (19.4%) and thalamic/basal ganglia (13.6%) compared to IDH1/2-mutant tumors (7.3% and 2.2%, respectively) (Fig. 5I). This evidence concerns the gene IDH1 and central nervous system cancer.